Efficacy and Safety of the Dual SGLT1 and SGLT2 Inhibitor JP-2266 in Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study
Diabetes & Metabolism Journal · 29.07.2026
DOI: 10.4093/dmj.2025.1152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes & Metabolism Journal, online erschienen am 29.07.2026. Verfasst von Eun Young Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of…. Die Arbeit nennt 30 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
- Division of Endocrinology, Department of Internal Medicine, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Korea.
- Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, Korea.
Zitieren
APA
Lee, E. Y., Han, K. A., Kwak, S. H., Hong, J. H., Hwang, Y. C., Koh, G., Hughes, J. W., Kim, S., Lee, C. S., & Cha, B. S. (2026). Efficacy and Safety of the Dual SGLT1 and SGLT2 Inhibitor JP-2266 in Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2025.1152
Vancouver
Lee EY, Han KA, Kwak SH, Hong JH, Hwang YC, Koh G, et al. Efficacy and Safety of the Dual SGLT1 and SGLT2 Inhibitor JP-2266 in Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study. Diabetes & Metabolism Journal. 2026. doi:10.4093/dmj.2025.1152
BibTeX
@article{Lee2026,
author = {Lee, Eun Young and Han, Kyung Ah and Kwak, Soo Heon and Hong, Jun Hwa and Hwang, You-Cheol and Koh, Gwanpyo and Hughes, Jing W and Kim, Soomee and Lee, Chang-Seok and Cha, Bong-Soo},
title = {Efficacy and Safety of the Dual SGLT1 and SGLT2 Inhibitor JP-2266 in Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study},
journal = {Diabetes & Metabolism Journal},
year = {2026},
doi = {10.4093/dmj.2025.1152}
}
EUVIMED